Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. 24 March 2021. Michael Gold.

Executive Summary

Results from a Medtronic-sponsored clinical trial of cardiac resynchronization therapy suggest pacemakers and defibrillators may be underutilized, said Michael Gold, a cardiologist at the Medical University of South Carolina, Charleston.

“We're depriving patients of therapy that may be lifesaving or may keep them from getting worse heart failure because we think that we shouldn't put [a device] in unless their heart function is going to return to normal. But that’s not what we do with medications or what we do in other therapies … We’d like them to get better … but if we can keep them from getting worse, that's [also] a good outcome.” – Michael Gold, cardiologist, Medical University of South Carolina, Charleston

Click here for a free trial of Medtech Insight

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts